- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2013
- Public Summary Document (PSD) July 2013 PBAC Meeting - PDF
Afatinib – July 2013
Afatinib, tablets, 20 mg, 30 mg, 40 mg and 50 mg, (as dimaleate) Giotrif® (second / third Line)
Last updated
8 November 2023